RPL27 contributes to colorectal cancer proliferation and stemness via PLK1 signaling

Park,So-Young; Seo,Daekwan; Jeon,Eun-Hye; Park,Jee Young; Jang,Byeong-Churl; Kim,Jee In; Im,Seung-Soon; Lee,Jae-Ho; Kim,Shin; Cho,Chi Heum; Lee,Yun-Han

doi:10.3892/ijo.2023.5541

RPL27 contributes to colorectal cancer proliferation and stemness via PLK1 signaling

Authors:
- So-Young Park
- Daekwan Seo
- Eun-Hye Jeon
- Jee Young Park
- Byeong-Churl Jang
- Jee In Kim
- Seung-Soon Im
- Jae-Ho Lee
- Shin Kim
- Chi Heum Cho
- Yun-Han Lee
View Affiliations

Affiliations: Department of Molecular Medicine, Keimyung University School of Medicine, Daegu 42601, Republic of Korea, Department of Bioinformatics, Psomagen Inc., Rockville, MD 20850, USA, Department of Immunology, Keimyung University School of Medicine, Daegu 42601, Republic of Korea, Department of Physiology, Keimyung University School of Medicine, Daegu 42601, Republic of Korea, Department of Anatomy, Keimyung University School of Medicine, Daegu 42601, Republic of Korea, Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu 42601, Republic of Korea
Published online on: June 29, 2023 https://doi.org/10.3892/ijo.2023.5541
Article Number: 93
Copyright: © Park et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although expression of ribosomal protein L27 (RPL27) is upregulated in clinical colorectal cancer (CRC) tissue, to the best of our knowledge, the oncogenic role of RPL27 has not yet been defined. The present study aimed to investigate whether targeting RPL27 could alter CRC progression and determine whether RPL27 gains an extra‑ribosomal function during CRC development. Human CRC cell lines HCT116 and HT29 were transfected with RPL27‑specific small interfering RNA and proliferation was assessed in vitro and in vivo using proliferation assays, fluorescence‑activated cell sorting (FACS) and a xenograft mouse model. Furthermore, RNA sequencing, bioinformatic analysis and western blotting were conducted to explore the underlying mechanisms responsible for RPL27 silencing‑induced CRC phenotypical changes. Inhibiting RPL27 expression suppressed CRC cell proliferation and cell cycle progression and induced apoptotic cell death. Targeting RPL27 significantly inhibited growth of human CRC xenografts in nude mice. Notably, polo‑like kinase 1 (PLK1), which serves an important role in mitotic cell cycle progression and stemness, was downregulated in both HCT116 and HT29 cells following RPL27 silencing. RPL27 silencing reduced the levels of PLK1 protein and G2/M‑associated regulators such as phosphorylated cell division cycle 25C, CDK1 and cyclin B1. Silencing of RPL27 reduced the migration and invasion abilities and sphere‑forming capacity of the parental CRC cell population. In terms of phenotypical changes in cancer stem cells (CSCs), RPL27 silencing suppressed the sphere‑forming capacity of the isolated CD133⁺ CSC population, which was accompanied by decreased CD133 and PLK1 levels. Taken together, these findings indicated that RPL27 contributed to the promotion of CRC proliferation and stemness via PLK1 signaling and RPL27 may be a useful target in a next‑generation therapeutic strategy for both primary CRC treatment and metastasis prevention.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E and Norat T: Red and processed meat and colorectal cancer incidence: Meta-analysis of prospective studies. PLoS One. 6:e204562011. View Article : Google Scholar : PubMed/NCBI
3	Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, Negri E, Straif K, Romieu I, La Vecchia C, et al: Alcohol drinking and colorectal cancer risk: An overall and dose-response meta-analysis of published studies. Ann Oncol. 22:1958–1972. 2011. View Article : Google Scholar : PubMed/NCBI
4	Jo A and Oh H: Incidence of colon cancer related to cigarette smoking and alcohol consumption in adults with metabolic syndrome: Prospective cohort study. J Korean Acad Nurs. 49:713–723. 2019.In Korean. View Article : Google Scholar
5	von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW and Tekkis PP: The risk of cancer in patients with Crohn's disease. Dis Colon Rectum. 50:839–855. 2007. View Article : Google Scholar : PubMed/NCBI
6	Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y and Qin H: Obesity and risk of colorectal cancer: A systematic review of prospective studies. PLoS One. 8:e539162013. View Article : Google Scholar : PubMed/NCBI
7	Jiang Y, Ben Q, Shen H, Lu W, Zhang Y and Zhu J: Diabetes mellitus and incidence and mortality of colorectal cancer: A systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 26:863–876. 2011. View Article : Google Scholar : PubMed/NCBI
8	Taylor DP, Burt RW, Williams MS, Haug PJ and Cannon-Albright LA: Population-based family history-specific risks for colorectal cancer: A constellation approach. Gastroenterology. 138:877–885. 2010. View Article : Google Scholar
9	Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
10	Bahnassy AA, Zekri AR, Salem SE, Abou-Bakr AA, Sakr MA, Abdel-Samiaa AG and Al-Bradei M: Differential expression of p53 family proteins in colorectal adenomas and carcinomas: Prognostic and predictive values. Histol Histopathol. 29:207–216. 2014.
11	Mody K, Baldeo C and Bekaii-Saab T: Antiangiogenic therapy in colorectal cancer. Cancer J. 24:165–170. 2018. View Article : Google Scholar : PubMed/NCBI
12	Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, André T and de Gramont A: Therapeutic strategy in unresectable metastatic colorectal cancer: An updated review. Ther Adv Med Oncol. 7:153–169. 2015. View Article : Google Scholar : PubMed/NCBI
13	O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. 2007. View Article : Google Scholar
14	Kozovska Z, Gabrisova V and Kucerova L: Colon cancer: Cancer stem cells markers, drug resistance and treatment. Biomed Pharmacother. 68:911–916. 2014. View Article : Google Scholar : PubMed/NCBI
15	Braun MS and Seymour MT: Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol. 3:43–52. 2011. View Article : Google Scholar : PubMed/NCBI
16	Soueidy C, Skaff S, Stephan F and Kattan J: Cetuximab severe cutaneous toxicity a gateway for bacteremia: Case report. Anticancer Drugs. 34:187–189. 2023. View Article : Google Scholar
17	Hu CY, Chan W, Delclos GP and Du XL: Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer. Am J Clin Oncol. 35:228–236. 2012. View Article : Google Scholar
18	Cai Y, Zhang C, Hao L, Chen J, Xie P and Chen Z: Systematic identification of seven ribosomal protein genes in bighead carp and their expression in response to microcystin-LR. J Toxicol Sci. 41:293–302. 2016. View Article : Google Scholar : PubMed/NCBI
19	Montanaro L, Treré D and Derenzini M: Nucleolus, ribosomes, and cancer. Am J Pathol. 173:301–310. 2008. View Article : Google Scholar : PubMed/NCBI
20	Derenzini M, Montanaro L and Trerè D: Ribosome biogenesis and cancer. Acta Histochem. 119:190–197. 2017. View Article : Google Scholar : PubMed/NCBI
21	Donati G, Bertoni S, Brighenti E, Vici M, Treré D, Volarevic S, Montanaro L and Derenzini M: The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells. Oncogene. 30:3274–3288. 2011. View Article : Google Scholar : PubMed/NCBI
22	Baik IH, Jo GH, Seo D, Ko MJ, Cho CH, Lee MG and Lee YH: Knockdown of RPL9 expression inhibits colorectal carcinoma growth via the inactivation of Id-1/NF-κB signaling axis. Int J Oncol. 49:1953–1962. 2016. View Article : Google Scholar : PubMed/NCBI
23	Ko MJ, Seo YR, Seo D, Park SY, Seo JH, Jeon EH, Kim SW, Park KU, Koo DB, Kim S, et al: RPL17 promotes colorectal cancer proliferation and stemness through ERK and NEK2/β-catenin signaling pathways. J Cancer. 13:2570–2583. 2022. View Article : Google Scholar :
24	Liu F, Li Y, Yu Y, Fu S and Li P: Cloning of novel tumor metastasis-related genes from the highly metastatic human lung adenocarcinoma cell line Anip973. J Genet Genomics. 34:189–195. 2007. View Article : Google Scholar : PubMed/NCBI
25	Dave B, Gonzalez DD, Liu ZB, Li X, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD, et al: Role of RPL39 in metaplastic breast cancer. J Natl Cancer Inst. 109:djw2922016. View Article : Google Scholar
26	Hide T, Shibahara I, Inukai M, Shigeeda R and Kumabe T: Ribosomes and ribosomal proteins promote plasticity and stemness induction in glioma cells via reprogramming. Cells. 11:21422022. View Article : Google Scholar : PubMed/NCBI
27	Sim EU, Bong IP, Balraj P, Tan SK, Jamal R, Sagap I, Nadeson S, Rose IM and Lom PKM: A preliminary study of differentially expressed genes in Malaysian colorectal carcinoma cases. Trop Life Sci Res. 17:19–37. 2006.
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
29	McHugh ML: Multiple comparison analysis testing in ANOVA. Biochem Med (Zagreb). 21:203–209. 2011. View Article : Google Scholar : PubMed/NCBI
30	Riccardi C and Nicoletti I: Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 1:1458–1461. 2006. View Article : Google Scholar
31	Han DP, Zhu QL, Cui JT, Wang PX, Qu S, Cao QF, Zong YP, Feng B, Zheng MH and Lu AG: Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med Sci Monit. 18:BR237–BR246. 2012. View Article : Google Scholar : PubMed/NCBI
32	Gutteridge RE, Ndiaye MA, Liu X and Ahmad N: Plk1 inhibitors in cancer therapy: From laboratory to clinics. Mol Cancer Ther. 15:1427–1435. 2016. View Article : Google Scholar : PubMed/NCBI
33	Bhosale PB, Vetrivel P, Ha SE, Kim HH, Heo JD, Won CK, Kim SM and Kim GS: Iridin Induces G2/M phase cell cycle arrest and extrinsic apoptotic cell death through PI3K/AKT signaling pathway in AGS gastric cancer cells. Molecules. 26:28022021. View Article : Google Scholar : PubMed/NCBI
34	Zhang Z, Zhang G, Gao Z, Li S, Li Z, Bi J, Liu X, Li Z and Kong C: Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer. BMC Cancer. 17:8612017. View Article : Google Scholar : PubMed/NCBI
35	Song R, Hou G, Yang J, Yuan J, Wang C, Chai T and Liu Z: Effects of PLK1 on proliferation, invasion and metastasis of gastric cancer cells through epithelial-mesenchymal transition. Oncol Lett. 16:5739–5744. 2018.PubMed/NCBI
36	Wu ZY and Wei N: Knockdown of PLK1 inhibits invasion and promotes apoptosis in glioma cells through regulating autophagy. Eur Rev Med Pharmacol Sci. 22:2723–2733. 2018.PubMed/NCBI
37	Gao J, Yang T, Wang X, Zhang Y, Wang J, Zhang B, Tang D, Liu Y, Gao T, Lin Q, et al: Identification and characterization of a subpopulation of CD133⁺ cancer stem-like cells derived from SK-UT-1 cells. Cancer Cell Int. 21:1572021. View Article : Google Scholar
38	Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Hemmat N, Derakhshani A, Brunetti O, Safaei S, et al: The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. Biomed Pharmacother. 137:1113642021. View Article : Google Scholar : PubMed/NCBI
39	Francescangeli F, Patrizii M, Signore M, Federici G, Di Franco S, Pagliuca A, Baiocchi M, Biffoni M, Ricci Vitiani L, Todaro M, et al: Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Stem Cells. 30:1819–1830. 2012. View Article : Google Scholar : PubMed/NCBI
40	Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M, Irwin MS, Wrana JL, Al-Awar R and Kaplan DR: Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res. 71:1385–1395. 2011. View Article : Google Scholar : PubMed/NCBI
41	Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y and Saji S: Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 94:148–152. 2003. View Article : Google Scholar : PubMed/NCBI
42	Golsteyn RM, Lane HA, Mundt KE, Arnaud L and Nigg EA: The family of polo-like kinases. Prog Cell Cycle Res. 2:107–114. 1996.PubMed/NCBI
43	Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G, et al: Polo-like kinase 1: A potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res. 73:813–823. 2013. View Article : Google Scholar
44	Zhang G, Zhang Z and Liu Z: Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells. Tumour Biol. 34:1887–1894. 2013. View Article : Google Scholar : PubMed/NCBI
45	He ZL, Zheng H, Lin H, Miao XY and Zhong DW: Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol. 15:4177–4182. 2009. View Article : Google Scholar : PubMed/NCBI
46	Yoon HE, Kim SA, Choi HS, Ahn MY, Yoon JH and Ahn SG: Inhibition of Plk1 and Pin1 by 5′-nitro-indirubinoxime suppresses human lung cancer cells. Cancer Lett. 316:97–104. 2012. View Article : Google Scholar
47	van de Weerdt BC and Medema RH: Polo-like kinases: A team in control of the division. Cell Cycle. 5:853–864. 2006. View Article : Google Scholar : PubMed/NCBI
48	Liu X and Erikson RL: Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA. 100:5789–5794. 2003. View Article : Google Scholar : PubMed/NCBI
49	Spänkuch B, Kurunci-Csacsko E, Kaufmann M and Strebhardt K: Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene. 26:5793–5807. 2007. View Article : Google Scholar : PubMed/NCBI
50	Gavet O and Pines J: Activation of cyclin B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis. J Cell Biol. 189:247–259. 2010. View Article : Google Scholar : PubMed/NCBI
51	Hsiao YC, Hsieh YS, Kuo WH, Chiou HL, Yang SF, Chiang WL and Chu SC: The tumor-growth inhibitory activity of flavanone and 2′-OH flavanone in vitro and in vivo through induction of cell cycle arrest and suppression of cyclins and CDKs. J Biomed Sci. 14:107–119. 2007. View Article : Google Scholar
52	Kamijo T: Role of stemness-related molecules in neuroblastoma. Pediatr Res. 71:511–515. 2012. View Article : Google Scholar : PubMed/NCBI
53	Hu K, Law JH, Fotovati A and Dunn SE: Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res. 14:R222012. View Article : Google Scholar : PubMed/NCBI
54	Zhang H, Li W, Nan F, Ren F, Wang H, Xu Y and Zhang F: MicroRNA expression profile of colon cancer stem-like cells in HT29 adenocarcinoma cell line. Biochem Biophys Res Commun. 404:273–278. 2011. View Article : Google Scholar